GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Hualan Biological Engineering 002007.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

12.17

-1.06%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥4.58bn

FY2016FY2025

Net income

CN¥940.4m

FY2016FY2025

Free cash flow

CN¥944.7m

FY2016FY2025

Shareholders' equity

CN¥11.50bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥4.58bnCN¥4.38bnCN¥5.34bnCN¥4.52bnCN¥4.44bnCN¥5.02bnCN¥3.70bnCN¥3.22bnCN¥2.37bnCN¥1.93bn
Gross profitCN¥2.51bnCN¥2.61bnCN¥3.61bnCN¥2.82bnCN¥2.90bnCN¥3.62bnCN¥2.35bnCN¥2.09bnCN¥1.45bnCN¥1.16bn
Research and developmentCN¥295.8mCN¥333.2mCN¥280.8mCN¥314.7mCN¥253.6mCN¥213.2mCN¥143.5mCN¥146.5mCN¥129.4mCN¥98.6m
Operating incomeCN¥1.13bnCN¥1.38bnCN¥2.10bnCN¥1.22bnCN¥1.70bnCN¥2.15bnCN¥1.62bnCN¥1.39bnCN¥916.0mCN¥837.7m
Net incomeCN¥940.4mCN¥1.09bnCN¥1.48bnCN¥1.08bnCN¥1.30bnCN¥1.61bnCN¥1.28bnCN¥1.14bnCN¥820.8mCN¥780.3m
Diluted earnings per share0.510.590.810.590.710.880.700.630.450.43

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥15.26bnCN¥16.31bnCN¥16.11bnCN¥14.74bnCN¥11.54bnCN¥10.04bnCN¥7.58bnCN¥6.49bnCN¥5.22bnCN¥4.65bn
Cash and short-term investmentsCN¥4.30bnCN¥3.25bnCN¥3.11bnCN¥3.47bnCN¥3.35bnCN¥4.02bnCN¥3.37bnCN¥2.46bnCN¥1.49bnCN¥1.79bn
Total liabilitiesCN¥1.81bnCN¥2.46bnCN¥2.68bnCN¥2.53bnCN¥2.47bnCN¥1.94bnCN¥699.3mCN¥720.5mCN¥377.2mCN¥215.1m
DebtCN¥547.2mCN¥908.5mCN¥709.5mCN¥1.11bnCN¥990.7mCN¥400.0m————
Shareholders' equityCN¥11.50bnCN¥11.86bnCN¥11.36bnCN¥10.40bnCN¥8.34bnCN¥7.53bnCN¥6.54bnCN¥5.53bnCN¥4.67bnCN¥4.22bn
Shares outstanding1,826m1,829m1,824m1,830m1,826m1,824m1,824m1,814m1,814m1,814m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥1.14bnCN¥1.06bnCN¥1.35bnCN¥957.3mCN¥1.43bnCN¥1.33bnCN¥1.36bnCN¥1.29bnCN¥177.4mCN¥329.9m
Capital spending−CN¥197.3m−CN¥255.8m−CN¥753.4m−CN¥393.9m−CN¥811.3m−CN¥621.4m−CN¥273.0m−CN¥183.3m−CN¥108.5m−CN¥220.7m
Free cash flowCN¥944.7mCN¥803.6mCN¥592.4mCN¥563.4mCN¥621.1mCN¥703.9mCN¥1.09bnCN¥1.11bnCN¥68.9mCN¥109.3m
Dividends paid−CN¥1.36bn−CN¥467.8m−CN¥563.6m−CN¥364.9m−CN¥564.1m−CN¥561.3m−CN¥390.6m−CN¥275.3m−CN¥397.0m−CN¥232.5m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥804.5mCN¥762.1mCN¥1.22bnCN¥1.58bnCN¥930.6mCN¥867.6mCN¥888.5mCN¥1.84bn
Gross profitCN¥341.3mCN¥382.5mCN¥666.5mCN¥1.00bnCN¥467.7mCN¥488.3mCN¥454.7mCN¥1.32bn
Operating incomeCN¥110.0mCN¥218.9mCN¥238.1mCN¥355.9mCN¥237.6mCN¥397.5mCN¥157.7mCN¥682.9m
Net incomeCN¥153.0mCN¥230.3mCN¥156.0mCN¥268.6mCN¥202.7mCN¥313.1mCN¥164.2mCN¥483.5m
Diluted earnings per share0.080.130.090.150.110.170.090.26
Cash from operations——CN¥495.0mCN¥319.0mCN¥216.0mCN¥14.0mCN¥599.0mCN¥138.0m
Capital spending−CN¥27.0m−CN¥51.0m−CN¥48.0m−CN¥36.0m−CN¥44.0m−CN¥67.0m−CN¥201.0m−CN¥197.0m
Free cash flow——CN¥447.0mCN¥283.0mCN¥172.0m−CN¥53.0mCN¥398.0m−CN¥59.0m
Total assetsCN¥14.55bnCN¥15.06bnCN¥15.26bnCN¥16.27bnCN¥15.54bnCN¥16.64bnCN¥16.31bnCN¥16.10bn
Cash and short-term investments——CN¥4.30bnCN¥4.08bnCN¥2.93bnCN¥3.65bnCN¥3.25bnCN¥2.62bn
Debt——CN¥538.8mCN¥467.9mCN¥280.0mCN¥1.08bnCN¥899.7mCN¥600.0m
Shareholders' equityCN¥10.97bnCN¥11.72bnCN¥11.50bnCN¥11.37bnCN¥12.01bnCN¥12.17bnCN¥11.86bnCN¥11.70bn

Financial ratios

Data as of 23 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin54.9%59.6%67.7%62.4%65.3%72.0%
Operating margin24.7%31.5%39.3%27.1%38.2%42.8%
Net margin20.6%24.8%27.7%23.8%29.3%32.1%
Return on equity8.2%9.2%13.0%10.4%15.6%21.4%
Return on assets6.2%6.7%9.2%7.3%11.3%16.1%
Free cash flow yield5.5%5.4%8.7%5.6%9.2%8.0%
Revenue growth4.5%-18.0%18.3%1.8%-11.7%35.8%
Earnings growth-13.6%-26.6%37.7%-17.1%-19.5%25.7%
Current ratio4.93x4.07x3.61x3.76x3.09x3.92x
Debt to equity0.05x0.08x0.06x0.11x0.12x0.05x
Equity ratio75.4%72.7%70.5%70.5%72.3%75.0%
Interest coverage104.64x102.64x155.94x39.92x76.90x397.44x
R&D as a share of sales6.5%7.6%5.3%7.0%5.7%4.2%
Buybacks as a share of market value0.2%-0.2%0.3%-0.2%-0.1%0.0%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue0.4%-1.8%12.0%
Operating income-2.6%-12.1%5.4%
Net income-4.4%-10.2%4.8%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin57.2%61.4%63.9%63.4%
Operating margin28.0%31.0%34.2%36.9%
Net margin22.6%24.4%26.5%29.6%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings29.428.327.338.541.047.838.426.830.542.6
Price to sales6.07.07.69.212.015.313.39.510.617.2

Dividends and splits

Per share, in the currency the company pays

Paid for 17 years. Last went ex-dividend on 27 Oct 2025.

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Paid in the year0.700.300.300.200.300.3080.2050.154
  • 13-for-10 split · 27 Apr 2020
  • 3-for-2 split · 17 Jun 2019
  • 8-for-5 split · 7 Jun 2016
  • 8-for-5 split · 27 May 2010
  • 8-for-5 split · 6 May 2009
  • 6-for-5 split · 24 Oct 2007

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.